Clinical Trial Update: Study of the Effect of Intravenous AVE0005 (VEGF Trap) in Advanced Ovarian Cancer Patients With Recurrent Symptomatic Malignant Ascites [Phase 2, Phase 3]

View source ↗

Summary

A completed Phase 2/3 trial evaluating intravenous AVE0005 (aflibercept) in advanced ovarian cancer with recurrent symptomatic malignant ascites. Results were p…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Ascites
• Ovarian Cancer

Drugs mentioned

• AVE0005 (VEGF Trap) (ziv-aflibercept)

Snippet

Sponsor: Sanofi | Conditions: Ovarian Neoplasms, Ascites | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2013-01-01